Nasal polyposis (NP) is a common chronic inflammatory disease of the rhinosinus mucosa and a complex disease with strong genetic and environmental components. During the past 10 to 20 yr, many studies have been performed to determine differential gene expression profiles between NP and normal nasal tissues, in order to identify susceptible genes that are associated with NP-related traits. Despite achievement in the identification of candidate genes and their associated pathogenic pathways, the large challenges remain as the genetic and molecular alterations required for its development and progression are still unclear. Therefore, the development of novel, powerful tools for gene discovery, and a closer integration of genetics and medical biology would provide valuable insight into the pathogenesis of NP.

**Key Words.** Nasal polyposis, Genetics, Gene expression profile, Pathogenesis and pathophysiology, Susceptible genes and pathways

**INTRODUCTION**

Nasal polyposis (NP) is one of the most common mass lesions of the nose and was first described 4,000 yr ago in ancient Egypt. The prevalence of NP is reported from 0.2% to 4.3% worldwide, with a ratio of 2:1 between males and females (1). In children, NP is relatively rare and has a close relationship with asthma and cystic fibrosis (2). NP is a multifactorial condition which is often associated with many diseases and pathogenic disorders, such as allergy, infection, cystic fibrosis, asthma, and aspirin intolerance (1). However, the underlying mechanisms interlinking these pathologic conditions to NP formation remain unclear.

NPs are outgrowths of nasal mucosa which are smooth, semitranslucent, gelatinous and pale. Histo-morphological characterization of polytissue reveals frequent epithelial damage, a thickened basement membrane, and oedematous to sometimes fibrotic stromal tissue, with a reduced number of vessels and glands, but virtually no neural structure (3). Hellquist (4) divided NPs into four histological patterns. The most common type was the edematous NP with predominant eosinophilia, which constituted 85-90% of NPs. Other types include fibroinflammatory, hyperplasia of seromucinous glands and atypical stroma. It is not clear whether this classification has an impact on the differentiation of pathogenic mechanisms and clinical management of NPs.

Although the mechanisms involved in the pathogenesis of NP remain largely unclear, there are reports suggesting an underlying genetic predisposition. This concept is supported by some clinical data and genetic studies. This paper reviews recent understanding of the pathogenic mechanisms of NPs, which are influenced by a complex immune procedure including interaction of multiple genes. This review paper does not include NP in cystic fibrosis (CF), which is known to be a hereditary disease with multi-systemic involvement with genetic variations, presenting with defect in chloride transport across membranes and dehydrated secretions.

**FAMILY AND TWIN STUDIES OF NPS**

An interesting observation is that NP is frequently found to run in families, suggesting a hereditary or shared environmental factor. In the study by Rugina et al. (5), more than half of 224 NP patients (52%) had a positive family history of NP. The presence of NP was considered when NP had been diagnosed by an ENT practitioner or the patients had undergone sinus surgery for NP. A lower percentage (14%) of familial occurrence of NP was reported earlier by Greisner and Settipane (6) in a smaller group (n=50) of adult patients with NP. Thus, these results strongly suggest the existence of a hereditary factor in the pathogenesis of NP.

However, studies of monozygotic twins have not shown that...
both siblings always develop polyps, indicating that environmental factors are likely to influence the occurrence of NP (7, 8). NPs have been described in identical twins, but given the prevalence of nasal polyps, it might be expected that there would be more than a rare report of this finding (9).

**LINKAGE ANALYSIS AND ASSOCIATION STUDIES ASSOCIATED WITH NPS**

In the literature, some studies were able to show linkage of certain phenotypes of NP to candidate gene polymorphisms. Karjalainen et al. (10) reported that subjects with a single G-to-T polymorphism in exon 5 at +4,845 of the gene encoding IL-1 alpha (IL-1A) were found to have lower risk of developing NP as compared to subjects with common G/G genotype. In another study, polymorphism of IL-4 (IL-4-590 C/T), a potential determinant of IgE mediated allergic disease, was also found to be associated with a protective mechanism against NPs in the Korean populations (11). Recently, another asthma-related Arg16gly polymorphism of the beta2-adrenoceptor gene (ADRBeta2) was found to be associated with an increased risk of NP (12).

A number of genetic association studies found a significant correlation between certain human leukocyte antigen (HLA) alleles and NP. HLA is the general name of a group of genes in the human major histocompatibility complex (MHC) region on the human chromosome 6 that encodes the cell-surface antigen-presenting proteins. Luxenberger et al. (13) reported an association between HLA-A74 and NPs, whereas Molnar-Gabor et al. (14) reported that subjects carrying HLA-DR7-DQA1*0201 and HLA-DR7-DQB1*0202 haplotype had a 2 to 3 times odds ratio of developing NP. The risk of developing NP can be as high as 5.53 times in subjects with HLA-DQA1*0201-DQB1*0201 haplotype (15). Although several HLA alleles were found to be associated with NP, such susceptibility can be influenced by ethnicity. In the Mexican Mestizo population, increased frequency of the HLA-DRB1*03 allele and of the HLA-DRB1*04 allele were found in patients with NP as compared to healthy controls (16).

**MULTIPLE GENE EXPRESSIONS IN NASAL POLYPS**

The development and persistence of mucosal inflammation in NPs have been reported to be associated with numerous genes and potential single nucleotide polymorphisms (SNPs). The products of these genes determine various disease processes, such as immune modulation or immuno-pathogenesis, inflammatory cells (e.g., lymphocytes, eosinophils and neutrophils) development, activation, migration and life span, adhesion molecule expression, cytokine synthesis, cell-surface receptor display, and processes governing fibrosis and epithelial remodelling.

Gene profiling technologies have demonstrated considerable power in generation of cell and tissue molecular signatures and identification of disease-associated gene expression changes, and represent a rapid and efficient mean to elucidate alterations in cell signalling or metabolic pathways. DNA microarray technology consists of a matrix with attached sequences that allow simultaneous analysis of expression of panels of human genes. Comparison of profiles of genes expressed in disease versus healthy tissues often highlights the involvement of both expected and unsuspected pathologic pathways.

In the literature, gene expression profiles in NPs have been performed by many studies, including the major repertoire of disease-related susceptibility genes or genotypic markers. With the advance of microassay technique, expression profiles of over 10,000 of known and novel genes can be detected. A recent study showed that in NP tissues, 192 genes were upregulated by at least 2-fold, and 156 genes were downregulated by at least 50% in NP tissues as compared to sphenoid sinuses mucosa (17). In another study (18), microarray analysis was used to investigate the expression profile of 491 immune-associated genes in NPs. The results showed that 87 genes were differentially expressed in the immune-associated gene profile of nasal polyps, and 15 genes showed differential expression in both NPs and healthy controls (turbinates). In other studies, alterations in expression profiles of susceptible genes may contribute to many putative underlying pathophysiological or pathogenic mechanisms of NPs.

**Genes associated with inflammation and immunopathogenesis in NPs**

NP is a chronic inflammatory disease of the mucous membranes in the nose and paranasal sinuses. The role of the immune system in the pathogenesis of this disease is still unknown. To date, many studies have reported significant changes in presence of numerous inflammatory cells, mediators, cytokines, chemokines, and other inflammatory and immune modulating components in NPs, indicating that chronic inflammation is an important factor in development of NPs irrespective of the etiology.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a Th2-skewed eosinophilic inflammation, whereas chronic rhinosinusitis without nasal polyps (CRSsNP) represents a predominant Th1 milieu (18). In this report, the authors were able to show a significantly lower forkhead box P3 (FOXP3) mRNA and transforming growth factor beta-1 (TGF-beta1) protein expression, but a significantly higher T-bet, GATA-3, IL-5, and IL-13 mRNA expression compared with the healthy controls (Table 1). This Th2-skewed eosinophilic inflammation was shown by a decreased expression of multiple antimicrobial innate immune markers, including toll-like receptor 9, human beta- defense 2 and surfactant protein A, in human sinonasal epithelial cells from CRSwNP. The authors suggested that the impaired mucosal innate immunity may contribute to microbial colonization (e.g., bacteria, fungi and etc.) and abnormal immune responses associat-
Table 1. Expression profile of genes associated with inflammation and immunopathogenesis in nasal polyposis

| Pathogenic pathway | Name of genes | Potential biological/immunologic functions |
|--------------------|---------------|-------------------------------------------|
| High/overexpressed | IL-17 and IL-17 receptor (18) | Proinflammatory cytokine |
|                    | Lysophosphatidic acid receptor (24) | Inflammatory cascade |
|                    | IL-37 (25) | Antimicrobial peptide |
|                    | Superoxide dismutases gene SOD3 and SOD1 (26) | Increased oxidative stress |
|                    | Human beta-defensin-2 (27) | A key element in the innate host defence mechanism |
|                    | Cyclooxygenase-1 (28) | Mucosal inflammation |
|                    | CD40 (29) | Regulation of inflammation |
|                    | IL-1 beta, IL-6, IL-8, and transforming growth factor beta (30) | Pathogenesis of NP (non-allergic pattern of inflammation) |
|                    | Granulocyte macrophage colony-stimulating factor | Local tissue inflammation |
| Low/underexpressed | Cyclooxygenase-2 (28, 33) | Mucosal inflammation |
|                    | Syk (34, 35) | Intracellular signal transduction in hemopoietic cells |
|                    | Forkhead box P3 (FOXP3) (19) | Transcription factors for T-cell subpopulations |
|                    | Toll-like receptor 9 (20) | Mucosal innate immunity |
|                    | Human beta-defensin 2 (20) | Mucosal innate immunity |
|                    | Surfactant protein A (20) | Mucosal innate immunity |
|                    | B-Raf and Raf kinase inhibitor protein (36) | Endogenous inhibitors of the MAPK pathway |
|                    | Toll-like receptor 9 (22) | Impaired innate immunity |

Table 2. Expression profile of genes associated with the biological functions of inflammatory cells in nasal polyposis

| Pathogenic pathway | Name of genes | Potential biological/immunologic functions |
|--------------------|---------------|-------------------------------------------|
| High/overexpressed | Regulated upon activation, normal T expressed and secreted (41, 42, 43) | Eosinophil recruitment |
|                    | IL-5 (44, 45, 46) | Biological functions of eosinophils |
|                    | Aquaporin-1 (47) | Survival of eosinophils |
|                    | Protein kinase C (48) | Apoptosis inhibition (eosinophils) |
|                    | Eotaxin (42, 49, 50) | Enhance self-amplification process (eosinophils) |
|                    | Growth-related oncogene-alpha (51) | Recruitment and activation of neutrophils |
|                    | Stem cell factor (52) | Master cell growth and survival factor |
|                    | C-C Chemokine ligand 2 (53) | Recruitment of macrophages |
|                    | Regulator of G-protein signaling 1 (54) | Cell signal transduction |
|                    | IL-8 (54) | Releasing inflammatory factors |
|                    | Survivin (55) | Cell apoptosis |

ed with CRSwNP (20). In another study, an increased expression level of complement component C1q in NPs is suggested to be indicative of an ongoing inflammatory response in the nasal mucosa of these patients (21).

Innate immune recognition of pathogens by sinonasal epithelial cells may play an important role in the pathogenesis of chronic mucosal inflammation in rhinosinusitis (CRS) (22, 23). In Table 1, alterations in expression levels of several genes associated with immunopathogenesis in nasal mucosal or NP tissues are indicative of an ongoing inflammation and impaired mucosal innate immunity in patients with CRS with or without NPs.

Biological functions of inflammatory cells in NPs
The general histopathological classification of NPs is eosinophil-dominated inflammation (80-90%), which appears to be a hallmark of Caucasian NPs (3). This statement is well supported by an increased expression of cytokines, chemokines and molecular markers, which are involved in the proliferation, migration, activation and survival of eosinophils (Table 2). In the literature, IL-5 and eotaxin are most frequently reported molecular markers in NPs, as they are essential for eosinophil development, activation and survival (3). The soluble IL-5Rα expression level was also found to be dramatically higher (up to 1,200 times) than IL-5 concentrations in NP (37).
In addition, infiltration of other types of inflammatory cells, especially lymphocytes and neutrophils, may also play an important role in the inflammatory process underlying the pathogenesis of NPs (38-40). In Table 2, increased expression levels of growth-related oncogene-alpha (GRO-alpha), stem cell factors (SCF) and C-C chemokine ligand 2 are associated with biological functions of neutrophils, mast cells and macrophages. Therefore, in NP studies, one may not rely solely on limited type of cells and number of molecular markers (e., g., IL-5 and eotaxin) as NP is a heterogeneous disease with complex pathogenic mechanisms involved.

Genes associated with structure modification of epithelium in NPs

Histomorphological characterisation of NP tissue reveals frequent epithelial damage, a thickened membrane, and oedematous to sometimes fibrotic stromal tissue, with a reduced number of vessels and glands, but virtually no neutral structure (3). Many genetic studies have resulted in an emphasis on the structure modification of the epithelium in NPs. Table 3 shows the changes in expression level of many important genes, which are associated with proliferations of nasal epithelial and endothelial cells, submucosal glandular cells, regulation of goblet cell mucins, tissue remodelling, angiogenesis, impaired electrolyte and water transport across the epithelial cells, epithelial barrier maintenance and repair, and etc. However, pathogenic mechanisms underlying the changes of these structural gene functions are not clear.

There are a number of genes which are involved in epithelial barrier maintenance and repair in the inflammatory state of chronic rhinosinusitis (CRS) with NPs. For example, carbonic anhydrase (CA) is a zinc metalloenzyme that participate in the biological processes of various fluid transporting epithelia, including ion and water transport. In this study, a decreased expression level of CA was found to be associated with impaired electrolyte and water transport across the epithelial cell, which will result in oedema of NP tissue (56). In another study, the level of epidermal growth factor receptor (EGFR) mRNA in human sinus mucosa was found to be statistically significantly increased compared with that in the healthy controls (57). It is therefore suggested by the authors that up-regulation of the EGFR cascade may have an important role regarding mucus production in the sinus mucosa of patients with CRS and CRS with NP associated with hyperplasia and metaplasia of epithelial goblet cells.

Epithelial differential and tissue remodelling is also reported to be involved in the development and pathogenic characterisation of NPs. It was reported that an increased expression level of PDGF-B, TGF-beta1, and lower expressions of lumican and biglycan were found in NPs as compared to the healthy controls (Table 3). However, controversial results of TGF-beta1 expression level were also reported by other studies, where the expression levels

| Pathogenic pathway | Name of genes | Potential biological/immunologic functions |
|--------------------|---------------|------------------------------------------|
| High/overexpressed | • Hepatocyte growth factor and c-Met proteins (58) | • Enhancing proliferation of epithelial cells and submucosal glandular cells |
|                    | • Proliferation cell nuclear antigen, apoptosis associate gene protein (Bcl-2 and Bax) (59) | • Proliferation activity in the epithelium |
|                    | • Basic fibroblast growth factor (60) | • Endothelial and epithelial proliferation |
|                    | • Keratinocyte growth factor (61) | • Nasal epithelial proliferation |
|                    | • PS3 (62) | • Epithelial proliferation activity |
|                    | • Mucin 1, MUC4, MUC5AC, MUC5B (63-68) | • Polyp formation and progression |
|                    | • Epidermal growth factor receptor (57, 69) | • Regulation of goblet cell mucins |
|                    | • Fas-L protein (70) | • Cystic degeneration of submucosal glands |
|                    | • Vascular permeability factor and vascular endothelial growth factor (71) | • Development of oedema in chronic inflammation |
|                    | • Platelet-derived growth factor-B chain (72) | • Chronic inflammation and tissue remodelling |
|                    | • Vascular endothelial growth factor A (73) | • Angiogenesis |
|                    | • Transforming growth factor beta1 (73) | • Angiogenesis and tissue remodelling |
|                    | • Insulin-like growth factor 1 (73) | • Angiogenesis |
|                    | • Fibroblast growth factor 2 (73) | • Angiogenesis? |
|                    | • Matrix metalloproteinase-9 (44) | • Zn2+ dependent endopeptidases. Degradation extracellular matrix and tissue edema |
| Low/underexpressed | • Lumican and biglycan (74) | • Remodelling of the extracellular matrix |
|                    | • Carbonic anhydrase isoenzymes (56) | • Impaired electrolyte and water transport across the epithelial cells |
|                    | • S100A7, S100A8, S100A7 (75) | • Epithelial barrier maintenance and repair |
|                    | • Serine protease inhibitor kazal type 5 (75) | • Epithelial barrier maintenance and repair |
|                    | • Transforming growth factor beta1 (19, 76, 77) | • Chemoattractant and proliferation factor for fibroblasts |
Table 4. Significant genes with other or unclear biological functions in nasal polyposis

| Pathogenic pathway | Name of genes | Potential biological/immunologic functions |
|--------------------|---------------|------------------------------------------|
| High/overexpressed | - Statherin; prolactin-induced protein; lactoferrin, and deleted in malignant brain tumor 1 (17) | To be identify |
|                    | - Mammaglobin (80) | Polyp growth (to be confirmed) |
|                    | - Met proto-oncogene (MET) (79) | Aspirin sensitivity |
|                    | - Protein phosphatase 1 regulatory subunit 9B (79) | Aspirin sensitivity |
| Low/underexpressed | - Clara cell 10-kd protein (17) | To be identify |
|                    | - Human glucocorticoid receptors-alpha (45, 81) | Inflammation and response to glucocorticosteroid treatment |
|                    | - Prolactin-induced protein (79) | Aspirin sensitivity |
|                    | - Zinc alpha2-glycoprotein (AZGP1) (79) | Aspirin sensitivity |
|                    | - H-ras (78) | Tumourigenesis |

of TGF-beta1 in NPs appeared to be low in NPs (Table 3).

**Significant genes with other or unclear biological functions in NPs**

Using a genome-wide expression microarray, some studies have reported a few genes with significant changes in expression profiles in NP tissue as compared to healthy controls (Table 4). However, the biological functions of some of these genes (e.g., plasma membrane intrinsic protein [PIP], deleted in malignant brain tumors 1 [DMBT1], Mammaglobin and CC10) underlying the pathogenic mechanisms of NP development are unclear and need to be investigated in future.

Mutation and differential expression of the ras family genes contributing to tumourigenesis either through the accumulation of mutations or by aberrant expression in a wide range of human cancers has been well demonstrated. However, a recent study found that K- and H-ras expression levels were elevated, whereas N-ras mRNA levels were lower in NPs and adjacent turbinates as compared to the healthy control tissues. K-ras mRNA levels were up-regulated in advanced-stage polyps, while N-ras levels were found elevated in small polyps (78). These findings suggest a potential key role for activated members of ras family genes in terms of their contribution to the development of NPs as well as to the hypertrophy of adjacent turbinates.

The presence of aspirin-intolerance in a patient with CRS with or without NPs is associated with a particularly persistent and treatment-resistant form of disease, coexisting usually with severe asthma and referred to as the “aspiring triad” (3). In a recent study, genome-wide expression microarray study was performed in 57 patients with three distinct phenotypes: 1) patients with chronic rhinosinusitis and sinonasal polyposis without a history of aspirin allergy (CRS group); 2) patients with chronic rhinosinusitis and sinonasal polyposis with a history of asthma and aspirin allergy (ASA group); and 3) patients with no history or clinical evidence of sinusitis, asthma, or aspirin allergy (control group) (79). This study was able to identify five genes (POSTN, MET, PIP, AZGP1, and PPP1R9B) that are likely to play a role in the pathogenesis of sinonasal polyps associated with CRS and ASA (Table 4).

**CONCLUSION**

The expression of gene products is regulated at multiple levels, such as during transcription, mRNA processing, translation, phosphorylation and degradation. Although some studies were able to show certain NP associated polymorphisms and genotypes, the present data is still fragmented. Same as for many common human diseases, inherited genetic variation appears to be critical but yet still largely unexplained. Future studies are needed to identify the key genes underlying the development or formation of NP and to investigate the interactions between genetic and environmental factors that influence the complex traits of this disease. Identifying the causal genes and variants in NP is important to the path towards improved prevention, diagnosis and treatment of NPs.

**REFERENCES**

1. Bateman ND, Fahy C, Woolford TJ. Nasal polyps: still more questions than answers. J Laryngol Otol. 2003 Jan;117(1):1-9.
2. Triglia JM, Nicollas R. Nasal and sinus polyposis in children. Laryngoscope. 1997 Jul;107(7):963-6.
3. Fokkens W, Lund V, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyposis group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007(20):1-136.
4. Hellquist HB. Nasal polyps update. Histopathology. Allergy Asthma Proc. 1996 Sep-Oct;17(5):237-42.
5. Rugina M, Serrano E, Klossek JM, Crampette L, Stoll D, Bebear JP, et al. Epidemiological and clinical aspects of nasal polyposis in France: the ORLI group experience. Rhinology. 2002 Jun;40(2):75-9.
6. Greisner WA 3rd, Settipane GA. Hereditary factor for nasal polyps. Allergy Asthma Proc. 1996 Sep-Oct;17(5):283-6.
7. Lockey RF, Rucknagel DL, Vanselow NA. Familial occurrence of asthma, nasal polyps and aspirin intolerance. Ann Intern Med. 1973 Jan;78(1):57-63.
8. Settipane GA. Asthma, aspirin intolerance and nasal polyps. N Engl
Clinical and Experimental Otorhinolaryngology

23. Figueiredo CR, Silva ID, Weckx LL. Inflammatory genes in nasal polyposis in asthmatic adults. Allergy. 2003 May;58(5):393-6.

22. Ramanathan M Jr, Lee WK, Dubin MG, Lin S, Spannhake EW, Lane GM. Increased eotaxin-mRNA expression in non-atopic and atopic nasal polyps: comparison study between healthy nasal mucosa and nasal polyps. Clin Exp Allergy. 1995;25(7):607-15.

21. Baruah P, Trimarchi M, Dumitriu IE, Dellantonio G, Doglioni C, Rovere-Querini P. The role of RANTES in nasal polyposis. Am J Rhinol. 2005 Jan-Feb;19(1):15-20.

20. Mullol J, Xaubet A, Gaya A, Roca-Ferrer J, Lopez E, Fernandez JC, et al. Cytokine gene expression and release from epithelial cells. A comparison study between healthy nasal mucosa and nasal polyps. Clin Exp Allergy. 1995;25(7):607-15.

19. Van Bruaene N, Perez-Novo CA, Basinski TM, Van Zele T, Holtappels G, Cerezo-Camacho O, Jimenez-Lucio R, et al. DQA1 and DQB1 polymorphism is associated with protection against nasal polyps in a Korean population. Am J Rhinol. 2006 Sep-Oct;20(5):550-3.

18. Wang X, Dong Z, Zhu DD, Guan B. Expression profile of immune-associated genes in nasal polyps: comparison study between healthy nasal mucosa and nasal polyps. Clin Exp Allergy. 1995;25(7):607-15.

17. Liu Z, Kim J, Sypek JP, Horton H, Oppenheim FG, et al. Gene expression profiles in human nasal polyp tissue studied by means of DNA microarray. J Allergy Clin Immunol. 2004 Oct;114(4):783-90.

16. Ramirez-Anguiano J, Yamamoto-Furusako JK, Barquera R, Beltran O, Alba-Hurtado A, Escamilla J, et al. Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps. Exp Mol Med. 2006 Oct 31;38(5):466-73.

15. Fajardo-Dolci G, Solorio-Abreu J, Romero-Alvarez JC, Zavaleta-Villa B, Cerezo-Camacho O, Jimenez-Lucio R, et al. DNA microarray. J Allergy Clin Immunol. 2004 Oct;114(4):783-90.

14. Molnar-Gabor E, Endreffy E, Rozsasi A. HLA-DRB1, -DQA1, and -DQB1 genotypes in patients with nasal polyps. Eur Arch Otorhinolaryngol. 2000;257(3):137-9.

13. Luxenberger W, Posch U, Berghold A, Hofmann T, Lang-Loidolt D. HLA patterns in patients with nasal polyposis. Eur Arch Otorhinolaryngol. 2000;257(3):137-9.

12. Bussu F, Tiziano FD, Giorgio A, Pinto AM, De Corso E, Angelozzi C, et al. Positive identification in situ of mRNA expression of IL-6, and IL-12, and the chemotactic cytokine RANTES in patients with chronic sinusitis and polypoid disease. J Allergy Clin Immunol. 2001;167(1):283-8.

11. Yea SS, Yang YI, Park SK, Jang WH, Lee SS, Seog DH, et al. Interleukin-1 induced chemokine production through the association of Syk with TNF receptor-associated factor-6 in nasal fibroblasts lines. J Immunol. 2001;167(1):283-8.

10. Zhang N, Holtappels G, Cunha C, Huang G, van Cauwenberge P, Bachtel U. Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps from southern China. Am J Rhinol. 2006 Jul-Aug;20(4):445-50.

9. Meyer JE, Bartels J, Goroth T, Sticherling M, Rudack C, Ross DA, et al. The role of RANTES in nasal polyposis. Am J Rhinol. 2005 Jan-Feb;19(1):15-20.

8. Bartels J, Maune S, Meyer JE, Kalke R, Schluter C, Rowert J, et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003 May;58(5):371-9.

7. Hao J, Pang YF, Wang YF. Diffuse mucosal inflammation in nasal polyps and adjacent middle turbinate. Otolaryngol Head Neck Surg. 2006 Feb;134(2):267-75.

6. Jareoncharsri P, Bunnag C, Tunsuriyawong P, Assasin P, Muangsomboon S. Clinical and histopathological classification of nasal polyps in Thais. Siriraj Hosp Gaz. 2002;54:689-97.

5. Zhang N, Holtappels G, Cunha C, Huang G, van Cauwenberge P, Bachtel U. Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps. Acta Otolaryngol. 1996 Jul;116(4):604-10.

4. Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, et al. RKIP and BRAF aberrations in human nasal polyps and the adjacent turbinates mucosa. Cancer Lett. 2008 Jun 18;264(2):288-98.

3. Gevaert P, Bachert C, Holtappels G, Novo CP, Van der Heyden J, Fransen L, et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003 May;58(5):371-9.

2. Zhao J, Wang TF, Wang YF. Diffuse mucosal inflammation in nasal polyps and adjacent middle turbinate. Otolaryngol Head Neck Surg. 2006 Feb;134(2):267-75.

1. Ramanathan M Jr. Lee WK, Spannhake EW, Lane AP, Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol. 2008 Mar-Apr;22(2):115-21.
48. Li M, Dong Z, Yang Z, Bai Y. Protein kinase C in proliferation and infiltration of eosinophils in nasal polyp. Chin Med J (Engl). 2003 Oct;116(10):1553-6.

49. Molinaro RJ, Bernstein JM, Koury ST. Localization and quantitation of eotaxin mRNA in human nasal polyps. Immunol Invest. 2003 Aug;32(3):143-54.

50. Shin SH, Park JY, Jeon CH, Choi JK, Lee SH. Quantitative analysis of eotaxin and RANTES messenger RNA in nasal polyps: association of tissue and nasal eosinophils. Laryngoscope. 2000 Aug;110(8):1353-7.

51. Cardelli LO, Bogefors J, Bjartell A, Adner M, Uddman R, Egesten A. Topical steroids do not downregulate expression of growth-related onco-gene-alpha in nasal polyps. Acta Otolaryngol. 2006 Apr;126(4):375-80.

52. Kim YK, Nakagawa N, Nakano K, Sulakvelidze I, Dolovich J, Denburg JT. Expression of basic fibroblast growth factor in nasal polyps. Ann Otol Rhinol Laryngol. 1998 Oct;107(10 Pt 1):891-7.

53. Shun CT, Lin SK, Hong CY, Kok SH, Juan YH, Wang CC, et al. C-C chemokine ligand 2 gene expression in nasal polyp fibroblasts: possible implication in the pathogenesis of nasal polyps. Ann Otol Rhinol Laryngol. 2005 Nov;114(11):879-85.

54. Liu B, Wu J, Fan J, Peng Y. Gene expression profiles in human nasal polyps studied by DNA microarray. Chin Med J (Engl). 2003 Oct;116(10):1839-42.

55. Qiu ZF, Han DM, Zhang L, Zhang W, Fan EZ, Cui SJ, et al. Expression of survivin and enhanced polypogenesis in nasal polyps. Am J Rhinol. 2008 Mar-Apr;22(2):106-10.

56. Kim TH, Lee HM, Lee SH, Kim HK, Lee JH, Oh KH. Down-regulation of carbonic anhydrase isoenzymes in nasal polyps. Laryngoscope. 2008 Oct;118(10):1856-61.

57. Ding GQ, Zheng CQ, Bagga SS. Up-regulation of the mucosal epidermal growth factor receptor gene in chronic rhinosinusitis and nasal polyposis. Arch Otolaryngol Head Neck Surg. 2007 Nov;133(11):1097-103.

58. Rho HS, Lee SH, Lee HM, Jung HH, Choi J, Park MK, et al. Overexpression of hepatocyte growth factor and its receptor c-Met in nasal polyps. Arch Otolaryngol Head Neck Surg. 2006 Sep;132(9):985-9.

59. Dong Z, Guan G, Wang C. Expression of cell proliferation and apoptosis genes associated protein on nasal polyps and its significance. Zhonghua Er Bi Yan Hou Ke Za Zhi. 2000 Dec;35(6):429-31.

60. Powers MR, Qu Z, LaGesse PC, Liebler JM, Wall MA, Rosenbaum JT. Expression of basic fibroblast growth factor in nasal polyps. Ann Otol Rhinol Laryngol. 1998 Oct;107(10 Pt 1):891-7.

61. Ishibashi T, Tanaka T, Nibu K, Ishimoto S, Kaga K. Keratinocyte growth factor and its receptor messenger RNA expression in nasal mucosa and nasal polyps. Ann Otol Rhinol Laryngol. 1998 Oct;107(10 Pt 1):885-90.

62. Ingle RR, Setzen G, Koltai PJ, Monte D, Pastore J, Jennings TA. p53 expression in benign lesions of the upper respiratory tract. Arch Otolaryngol Head Neck Surg. 1997 Mar;123(3):297-300.

63. Martinez-Anton A, Debois C, Garrido M, Roca-Ferrer J, Barranco C, Alomí I, et al. Mucin genes have different expression patterns in healthy and diseased upper airway mucosa. Clin Exp Allergy. 2006 Apr;36(4):448-57.

64. Ali MS, Wilson JA, Bennett M, Pearson JP. Mucin gene expression in nasal polyps. Acta Otolaryngol. 2005 Jun;125(6):618-24.

65. Young Kim J, Kim CH, Kim KS, Choi YS, Lee JG, Yoon JH. Extracellular signal-regulated kinase is involved in tumor necrosis factor-alpha-induced MUC5AC gene expression in cultured human nasal polyp epithelial cells. Acta Otolaryngol. 2004 Oct;124(8):953-7.

66. Kim CH, Song KS, Kim SS, Kim HU, Seong JK, Yoon JH. Expression of MUC5AC mRNA in the goblet cells of human nasal mucosa. Laryngoscope. 2000 Dec;110(12):2110-3.

67. Bai CH, Song SY, Kim YD. Effect of glucocorticoid on the MUC4 gene in nasal polyps. Laryngoscope. 2007 Dec;117(12):2169-73.

68. Ding GQ, Zheng CQ. The expression of MUC5AC and MUC5B mucin genes in the mucosa of chronic rhinosinusitis and nasal polyposis. J Rhinol. 2005 May-Jun;21(3):359-66.

69. Burgel PR, Escudier E, Coste A, Dao-Pick T, Ueki IF, Takeyama K, et al. Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps. J Allergy Clin Immunol. 2000 Oct;106(4):705-12.

70. Fang SY, Yang BC. Overexpression of Fas-ligand in human nasal polyps. Ann Otol Rhinol Laryngol. 2000 Mar;109(3):267-70.

71. Ito A, Hirota S, Mizuno H, Kawasaki Y, Takemura T, Nishiiura T, et al. Expression of vascular permeability factor (VPF/VEGF) messenger RNA by plasma cells: possible involvement in the development of edema in chronic inflammation. Pathol Int. 1995 Oct;45(10):715-20.

72. Ohno I, Nitta Y, Yamauchi K, Hoshi H, Homma M, Woolley K, et al. Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma. Am J Respir Cell Mol Biol. 1995 Dec;13(6):639-47.

73. Zaravinos A, Soufla G, Bizakis J, Spandidos DA. Expression analysis of VEGFA, FGFR2, TGF-beta1, EGF and IGF1 in human nasal polyp. Oncol Rep. 2008 Feb;19(2):385-91.

74. Lee SH, Park JH, Oh BH, Jung KY, Lee HM, Choi JO, et al. Analysis of proteoglycan gene messages in human nasal mucosa and nasal polyp using dot blot hybridization. Acta Otolaryngol. 2001 Apr;121(3-4):398-402.

75. Richer SL, Truong-Tran AQ, Conley DB, Carter R, Vermlyen D, Grammer LC, et al. Epithelial genes in chronic rhinosinusitis with and without nasal polyps. Am J Rhinol. 2008 May-Jun;22(3):228-34.

76. Rostkowska-Nadolska B, Kapral M, Mazurek U, Gawron W, Prus K, Rostkowski A, et al. Co-expression of the TGF-beta1 and TGF-beta2 isoforms in nasal polyps and in healthy mucosa. Postepy Hig Med Dosw (Online). 2007;61:702-7.

77. Figueredo CR, Santos RP, Silva ID, Weckx LL. Micorarray cDNA to identify inflammatory genes in nasal polyps. Am J Rhinol. 2007 Mar-Apr;21(2):231-5.

78. Zaravinos A, Bizakis J, Soufla G, Sourvinos G, Spandidos DA. Mutations and differential expression of the ras family genes in human nasal polyposis. Int J Oncol. 2007 Nov;31(5):1051-9.

79. Stankovic KM, Goldstein H, Reh DD, Platt MP, Metson R. Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. Laryngoscope. 2008 May;118(5):881-9.

80. Fritz SB, Terrell JE, Conner ER, Kukowska-Latallo JF, Baker JR. Nasal sensitivity in asthma. Laryngoscope. 2008 May;118(5):881-9.